Novartis Investigative Site

Laken 1020

0 studies enrolling now · 11 studies all time

What they study most

Asthma, Cryopyrin-Associated Periodic Syndromes, Enthesitis-related Arthritis, Familial Cold Autoinflammatory Syndrome, Hypertension, Juvenile Psoriatic Arthritis, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease, Sickle Cell Disease, Sickle Cell Disease (SCD), Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA)

Studies at this site

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — Recruiting now
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients — Completed
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) — Completed
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension — Completed
Efficacy of QAX576 in Asthma — Completed
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab — Completed
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. — Completed
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) — Stopped early
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease — Completed
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) — Completed
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload — Completed